Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-05-16

Clinical Trial Update: A Study of Evacetrapib in High-Risk Vascular Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of evacetrapib in high-risk vascular disease was terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Evacetrapib

Snippet

Sponsor: Eli Lilly and Company | Conditions: Cardiovascular Diseases | Phase 3 | Status: TERMINATED | Results posted: 2018-05-16